Invention Grant
- Patent Title: BTK inhibitor compounds
-
Application No.: US16758219Application Date: 2018-10-30
-
Publication No.: US11542249B2Publication Date: 2023-01-03
- Inventor: Kenneth James Henry, Jr. , Albert Khilevich , Steven Lee Kuklish , Katherine Marie Partridge , Steven James Quimby
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Dan L Wood
- International Application: PCT/US2018/058104 WO 20181030
- International Announcement: WO2019/089512 WO 20190509
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D403/14 ; A61P19/02
Abstract:
The invention provides BTK Inhibitor compounds of the formula pharmaceutically acceptable salts, pharmaceutical compositions thereof, and methods of using these compounds, salts, or compositions to treat autoimmune diseases such as Rheumatoid Arthritis.
Public/Granted literature
- US20200290997A1 BTK INHIBITOR COMPOUNDS Public/Granted day:2020-09-17
Information query
